RIPK1 inhibitors have been advanced into human clinical studies for the treatment of human inflammatory and degenerative diseases including inflammatory bowel diseases, rheumatoid arthritis, psoriasis, ALS and AD [5]. The gene discussed is RIPK1; the disease is amyotrophic lateral sclerosis.